APA (7th ed.) Citation

Hasan, H., Deek, M. P., Phillips, R., Hobbs, R. F., Malek, R., Radwan, N., . . . DeWeese, T. L. (2020). A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer, 20(1), 1. https://doi.org/10.1186/s12885-020-07000-2

Chicago Style (17th ed.) Citation

Hasan, Hamza, et al. "A Phase II Randomized Trial of RAdium-223 Dichloride and SABR Versus SABR for OligomEtastatic Prostate CaNcerS (RAVENS)." BMC Cancer 20, no. 1 (2020): 1. https://doi.org/10.1186/s12885-020-07000-2.

MLA (9th ed.) Citation

Hasan, Hamza, et al. "A Phase II Randomized Trial of RAdium-223 Dichloride and SABR Versus SABR for OligomEtastatic Prostate CaNcerS (RAVENS)." BMC Cancer, vol. 20, no. 1, 2020, p. 1, https://doi.org/10.1186/s12885-020-07000-2.